Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2008

01-12-2008

Diagnosis of Cystic Fibrosis

Authors: Karen Z. Voter, Clement L. Ren

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2008

Login to get access

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that results in abnormal viscous mucoid secretions in multiple organs and whose main clinical features are pancreatic insufficiency and chronic endobronchial infection. Although it was initially defined and diagnosed based on clinical features and sweat chloride measurement, an in vivo method of assessing CFTR function, the discovery of the CFTR gene in 1989 revealed a broad spectrum of CF phenotypes associated with specific CFTR gene mutations. In this article, we will review the indications for sweat testing, alternative techniques to diagnose CF, and the approach to patients with an ambiguous or indeterminate diagnosis of CF.
Literature
1.
go back to reference Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154:1229–1256PubMed Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154:1229–1256PubMed
2.
go back to reference National Newborn Screening and Genetics Resource Center (2003) National newborn screening report 2000. National Newborn Screening and Genetics Resource Center, San Antonio, TX National Newborn Screening and Genetics Resource Center (2003) National newborn screening report 2000. National Newborn Screening and Genetics Resource Center, San Antonio, TX
3.
go back to reference Andersen D (1938) Cystic fibrosis of the pandrease and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56:344–399 Andersen D (1938) Cystic fibrosis of the pandrease and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56:344–399
4.
go back to reference Di Sant'Agnese P (2001) Experiences of a pioneer researcher: discovery of the sweat electrolyte defect and the early medical history of cystic fibrosis. In: Doershuk C (ed) Cystic fibrosis in the 20th century. People, events, and progress. AM, Cleveland, OH Di Sant'Agnese P (2001) Experiences of a pioneer researcher: discovery of the sweat electrolyte defect and the early medical history of cystic fibrosis. In: Doershuk C (ed) Cystic fibrosis in the 20th century. People, events, and progress. AM, Cleveland, OH
5.
go back to reference Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23:545–549PubMed Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23:545–549PubMed
6.
go back to reference Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589–595PubMedCrossRef Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589–595PubMedCrossRef
7.
go back to reference Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073PubMedCrossRef Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073PubMedCrossRef
8.
go back to reference Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67:471–485PubMedCrossRef Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67:471–485PubMedCrossRef
10.
go back to reference Cystic Fibrosis Foundation (2006) Cystic fibrosis foundation patient registry. Cystic Fibrosis Foundation, Bethesda, MD Cystic Fibrosis Foundation (2006) Cystic fibrosis foundation patient registry. Cystic Fibrosis Foundation, Bethesda, MD
11.
go back to reference Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW et al (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005–1015PubMedCrossRef Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW et al (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005–1015PubMedCrossRef
12.
13.
14.
go back to reference LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr (2007) Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151:85–89PubMedCrossRef LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr (2007) Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151:85–89PubMedCrossRef
15.
go back to reference NCCLS (2000) Sweat testing: sample collection and quantitative analysis: approved guideline. National Committee for Clinical Laboratory Standards, Wayne, PA Document C34-A2. Clinical Laboratory Standards Institute formerly National Committee for Clinical Laboratory Standards NCCLS (2000) Sweat testing: sample collection and quantitative analysis: approved guideline. National Committee for Clinical Laboratory Standards, Wayne, PA Document C34-A2. Clinical Laboratory Standards Institute formerly National Committee for Clinical Laboratory Standards
16.
go back to reference Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M et al (2004) Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53:1–36 Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M et al (2004) Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53:1–36
18.
go back to reference De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J et al (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635PubMedCrossRef De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J et al (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635PubMedCrossRef
19.
20.
21.
go back to reference Hamosh A, FitzSimmons SC, Macek M Jr., Knowles MR, Rosenstein BJ, Cutting GR (1998) Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 132:255–259PubMedCrossRef Hamosh A, FitzSimmons SC, Macek M Jr., Knowles MR, Rosenstein BJ, Cutting GR (1998) Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 132:255–259PubMedCrossRef
22.
go back to reference Wine JJ, Kuo E, Hurlock G, Moss RB (2001) Comprehensive mutation screening in a cystic fibrosis center. Pediatrics 107:280–286PubMedCrossRef Wine JJ, Kuo E, Hurlock G, Moss RB (2001) Comprehensive mutation screening in a cystic fibrosis center. Pediatrics 107:280–286PubMedCrossRef
23.
go back to reference Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A et al (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487–496PubMedCrossRef Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A et al (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487–496PubMedCrossRef
24.
go back to reference Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ (1993) Mutations in CFTR associated with mild-disease-form Cl− channels with altered pore properties. Nature 362:160–164PubMedCrossRef Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ (1993) Mutations in CFTR associated with mild-disease-form Cl− channels with altered pore properties. Nature 362:160–164PubMedCrossRef
25.
go back to reference O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R (2006) Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 118:1260–1265PubMedCrossRef O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R (2006) Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 118:1260–1265PubMedCrossRef
27.
go back to reference Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A et al (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331:974–980PubMedCrossRef Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A et al (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331:974–980PubMedCrossRef
28.
go back to reference Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM (1990) Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 3:922–926PubMed Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM (1990) Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 3:922–926PubMed
29.
go back to reference Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455PubMedCrossRef Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455PubMedCrossRef
30.
go back to reference Sauder RA, Chesrown SE, Loughlin GM (1987) Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 111:353–358PubMedCrossRef Sauder RA, Chesrown SE, Loughlin GM (1987) Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 111:353–358PubMedCrossRef
31.
go back to reference Wagener JS, Sontag MK, Accurso FJ (2003) Newborn screening for cystic fibrosis. Curr Opin Pediatr 15:309–315PubMedCrossRef Wagener JS, Sontag MK, Accurso FJ (2003) Newborn screening for cystic fibrosis. Curr Opin Pediatr 15:309–315PubMedCrossRef
Metadata
Title
Diagnosis of Cystic Fibrosis
Authors
Karen Z. Voter
Clement L. Ren
Publication date
01-12-2008
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2008
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-008-8078-x

Other articles of this Issue 3/2008

Clinical Reviews in Allergy & Immunology 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.